JERSEY CITY, N.J., June 23, 2011 /PRNewswire/ — Aoxing
Pharmaceutical (NYSE Amex:
AXN) (“Aoxing Pharma”), a specialty pharmaceutical company
focusing on research, development, manufacturing and distribution
of narcotic and pain-management products, reported that in light of
the unusual market activity in the Company’s common stock today,
June 23, the NYSE staff has contacted the Company in accordance
with its usual practice. In response, the Company stated that its
policy is not to comment on unusual market activity or rumors.
About Aoxing Pharmaceutical Company, Inc.
Aoxing Pharmaceutical Company, Inc. is a US incorporated
specialty pharmaceutical company with its operations in China,
specializing in research, development, manufacturing and
distribution of a variety of narcotics and pain-management
products. Headquartered in Shijiazhuang City, outside Beijing,
Aoxing has the largest and most advanced manufacturing facility in
China for highly regulated narcotic medicines. Its facility is one
of the few GMP facilities licensed for the manufacture of narcotic
medicines by the Chinese State Food and Drug Administration (SFDA).
It has joint venture collaboration with Johnson Matthey Plc to
produce and market narcotics and neurological drugs in China. It
also has strategic alliance partnerships with QRxPharma, Phoenix
PharmaLabs, Inc. and American Oriental Bioengineering, Inc. For
more information, please visit: www.aoxingpharma.com.
Safe Harbor Statement from Aoxing Pharmaceutical Company,
Inc.
Statements contained in this communication not relating to
historical facts are forward-looking statements that are intended
to fall within the safe harbor rule for such statements under the
Private Securities Litigation Reform Act of 1995. The information
contained in the forward-looking stateme
‘/>”/>
